U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Diffuse Large B-Cell Lymphoma

MedGen UID:
1727043
•Concept ID:
C5419059
•
Neoplastic Process

Definition

Diffuse large B-cell lymphoma that has spread extensively to distant anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Diffuse Large B-Cell Lymphoma

Professional guidelines

PubMed

Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas.
Ferreri AJ, Dell'Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, Villa E
Oncology 2000 Apr;58(3):219-26. doi: 10.1159/000012104. PMID: 10765124

Recent clinical studies

Etiology

Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.
Wan M, Zhang W, Huang H, Fang X, Chen Y, Tian Y, Yao Y, Weng H, Chen Z, Yu L, Tian Y, Huang H, Li X, Hong H, Lin T
Clin Exp Med 2024 Mar 30;24(1):64. doi: 10.1007/s10238-024-01326-y. PMID: 38554186Free PMC Article
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.
Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, Vega F, Agarwal NK
Leuk Lymphoma 2022 Jun;63(6):1302-1313. Epub 2021 Dec 31 doi: 10.1080/10428194.2021.2020782. PMID: 34969327
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.
Fluge Ø, Mannsåker B, Torp A, Mjaaland I, Helgeland L, Klos J, Mella O, Berentsen S, Meyer P
Clin Lymphoma Myeloma Leuk 2018 Feb;18(2):125-135.e3. Epub 2017 Dec 24 doi: 10.1016/j.clml.2017.12.002. PMID: 29352718
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H, Miura K, Nakagawa M, Sugitani M, Amano Y, Kurita D, Sakagami M, Ohtake S, Uchino Y, Kodaira H, Iriyama N, Kobayashi S, Hojo A, Kobayashi Y, Hirabayashi Y, Kusuda M, Hatta Y, Nakayama T, Takei M
Leuk Lymphoma 2016 Dec;57(12):2784-2790. Epub 2016 Apr 13 doi: 10.3109/10428194.2016.1167205. PMID: 27071312
Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK, Bista A, Shafii B
Anticancer Res 2014 Sep;34(9):5117-20. PMID: 25202101

Diagnosis

Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.
Wan M, Zhang W, Huang H, Fang X, Chen Y, Tian Y, Yao Y, Weng H, Chen Z, Yu L, Tian Y, Huang H, Li X, Hong H, Lin T
Clin Exp Med 2024 Mar 30;24(1):64. doi: 10.1007/s10238-024-01326-y. PMID: 38554186Free PMC Article
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.
Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, Vega F, Agarwal NK
Leuk Lymphoma 2022 Jun;63(6):1302-1313. Epub 2021 Dec 31 doi: 10.1080/10428194.2021.2020782. PMID: 34969327
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD
Leuk Lymphoma 2019 Apr;60(4):894-903. Epub 2018 Oct 2 doi: 10.1080/10428194.2018.1515940. PMID: 30277102Free PMC Article
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, Bo J, Fan H, Zhang Y, Zhang YJ, Chen MX, Feng KC, Wang QS, Fu XB, Han WD
Clin Immunol 2014 Dec;155(2):160-75. Epub 2014 Oct 16 doi: 10.1016/j.clim.2014.10.002. PMID: 25444722
Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK, Bista A, Shafii B
Anticancer Res 2014 Sep;34(9):5117-20. PMID: 25202101

Therapy

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD
Leuk Lymphoma 2019 Apr;60(4):894-903. Epub 2018 Oct 2 doi: 10.1080/10428194.2018.1515940. PMID: 30277102Free PMC Article
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H, Miura K, Nakagawa M, Sugitani M, Amano Y, Kurita D, Sakagami M, Ohtake S, Uchino Y, Kodaira H, Iriyama N, Kobayashi S, Hojo A, Kobayashi Y, Hirabayashi Y, Kusuda M, Hatta Y, Nakayama T, Takei M
Leuk Lymphoma 2016 Dec;57(12):2784-2790. Epub 2016 Apr 13 doi: 10.3109/10428194.2016.1167205. PMID: 27071312
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, Bo J, Fan H, Zhang Y, Zhang YJ, Chen MX, Feng KC, Wang QS, Fu XB, Han WD
Clin Immunol 2014 Dec;155(2):160-75. Epub 2014 Oct 16 doi: 10.1016/j.clim.2014.10.002. PMID: 25444722
Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK, Bista A, Shafii B
Anticancer Res 2014 Sep;34(9):5117-20. PMID: 25202101
First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions.
Brusamolino E
Haematologica 2009 Sep;94(9):1194-8. doi: 10.3324/haematol.2009.011320. PMID: 19734413Free PMC Article

Prognosis

Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.
Wan M, Zhang W, Huang H, Fang X, Chen Y, Tian Y, Yao Y, Weng H, Chen Z, Yu L, Tian Y, Huang H, Li X, Hong H, Lin T
Clin Exp Med 2024 Mar 30;24(1):64. doi: 10.1007/s10238-024-01326-y. PMID: 38554186Free PMC Article
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD
Leuk Lymphoma 2019 Apr;60(4):894-903. Epub 2018 Oct 2 doi: 10.1080/10428194.2018.1515940. PMID: 30277102Free PMC Article
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H, Miura K, Nakagawa M, Sugitani M, Amano Y, Kurita D, Sakagami M, Ohtake S, Uchino Y, Kodaira H, Iriyama N, Kobayashi S, Hojo A, Kobayashi Y, Hirabayashi Y, Kusuda M, Hatta Y, Nakayama T, Takei M
Leuk Lymphoma 2016 Dec;57(12):2784-2790. Epub 2016 Apr 13 doi: 10.3109/10428194.2016.1167205. PMID: 27071312
Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK, Bista A, Shafii B
Anticancer Res 2014 Sep;34(9):5117-20. PMID: 25202101
First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions.
Brusamolino E
Haematologica 2009 Sep;94(9):1194-8. doi: 10.3324/haematol.2009.011320. PMID: 19734413Free PMC Article

Clinical prediction guides

Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.
Wan M, Zhang W, Huang H, Fang X, Chen Y, Tian Y, Yao Y, Weng H, Chen Z, Yu L, Tian Y, Huang H, Li X, Hong H, Lin T
Clin Exp Med 2024 Mar 30;24(1):64. doi: 10.1007/s10238-024-01326-y. PMID: 38554186Free PMC Article
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.
Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, Vega F, Agarwal NK
Leuk Lymphoma 2022 Jun;63(6):1302-1313. Epub 2021 Dec 31 doi: 10.1080/10428194.2021.2020782. PMID: 34969327
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.
Fluge Ø, Mannsåker B, Torp A, Mjaaland I, Helgeland L, Klos J, Mella O, Berentsen S, Meyer P
Clin Lymphoma Myeloma Leuk 2018 Feb;18(2):125-135.e3. Epub 2017 Dec 24 doi: 10.1016/j.clml.2017.12.002. PMID: 29352718
Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK, Bista A, Shafii B
Anticancer Res 2014 Sep;34(9):5117-20. PMID: 25202101
Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma.
Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T
Anticancer Res 2012 Nov;32(11):5051-7. PMID: 23155278

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...